Vor Biopharma Inc.
Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.
On June 8, 2024, the Board designated Robert Ang, M.B.B.S., M.B.A., the Company’s President and Chief Executive Officer and a director of the Company, as the Company’s interim principal financial officer
and Amy Quinlan, the Company’s Vice President of Finance, as the Company’s interim principal accounting officer, effective as of the Effective Date.
On June 4, 2024, Nathan Jorgensen, Ph.D., M.B.A., notified Vor Biopharma Inc. (the “Company”) of his resignation as Chief Financial Officer of the Company, effective as of June 21, 2024 (the “Effective Date”), in order to pursue a new opportunity.
Extracted from this filing and checked against the source text.
Robert Ang was appointed as Interim Principal Financial Officer at Vor Biopharma Inc..
On June 8, 2024, the Board designated Robert Ang, M.B.B.S., M.B.A., the Company’s President and Chief Executive Officer and a director of the Company, as the Company’s interim principal financial officerView on SEC.gov
Amy Quinlan was appointed as Interim Principal Accounting Officer at Vor Biopharma Inc..
and Amy Quinlan, the Company’s Vice President of Finance, as the Company’s interim principal accounting officer, effective as of the Effective Date.View on SEC.gov
Nathan Jorgensen resigned as Chief Financial Officer at Vor Biopharma Inc..
On June 4, 2024, Nathan Jorgensen, Ph.D., M.B.A., notified Vor Biopharma Inc. (the “Company”) of his resignation as Chief Financial Officer of the Company, effective as of June 21, 2024 (the “Effective Date”), in order to pursue a new opportunity.View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.